Patents by Inventor Matthew Farrer

Matthew Farrer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070161595
    Abstract: Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells.
    Type: Application
    Filed: October 12, 2006
    Publication date: July 12, 2007
    Applicants: Mayo Foundation for Medical Education and Research, Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Matthew Farrer, Demetrius Maraganore, Hans-Peter Vornlocher
  • Publication number: 20050186591
    Abstract: Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells.
    Type: Application
    Filed: November 17, 2004
    Publication date: August 25, 2005
    Inventors: David Bumcrot, Matthew Farrer, Demetrius Maraganore, Hans-Peter Vornlocher
  • Publication number: 20050014173
    Abstract: Nucleic acids and polypeptides are provided that are associated with PD. Methods and articles of manufacture for screening individuals for susceptibility to PD, including susceptibility to a specific PD phenotype, are also disclosed.
    Type: Application
    Filed: May 5, 2004
    Publication date: January 20, 2005
    Inventor: Matthew Farrer